These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2313732)

  • 1. Killer antibodies enter clinical trial against ovarian cancer.
    Kerkvliet GJ
    J Natl Cancer Inst; 1990 Apr; 82(7):549-50. PubMed ID: 2313732
    [No Abstract]   [Full Text] [Related]  

  • 2. Radioimmunotherapy of cancer: arming the missiles.
    Goldenberg DM; Griffiths GL
    J Nucl Med; 1992 Jun; 33(6):1110-2. PubMed ID: 1597724
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoclonal antibody therapy in intra-abdominal malignancies.
    Muggia FM
    Cancer Invest; 1990; 8(2):293-4. PubMed ID: 2205340
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trials available using radiolabeled MoAbs against colon cancer, lung cancer, ovarian cancer, and hepatic metastases.
    Oncology (Williston Park); 1990 Aug; 4(8):100-1. PubMed ID: 2145005
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
    Breitz HB; Weiden PL; Vanderheyden JL; Appelbaum JW; Bjorn MJ; Fer MF; Wolf SB; Ratliff BA; Seiler CA; Foisie DC
    J Nucl Med; 1992 Jun; 33(6):1099-109. PubMed ID: 1597723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy for ovarian cancer.
    Bookman MA
    Curr Opin Oncol; 1989 Oct; 1(1):112-8. PubMed ID: 2489941
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ; Fer M; Su FM; Breitz H; Thompson J; Goodgold H; Cain J; Heaps J; Weiden P
    Obstet Gynecol; 1993 Oct; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of radiation therapy in ovarian cancer.
    Moore DH
    Curr Opin Obstet Gynecol; 1990 Feb; 2(1):64-8. PubMed ID: 2102308
    [No Abstract]   [Full Text] [Related]  

  • 9. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.
    Breitz HB; Durham JS; Fisher DR; Weiden PL
    Cancer Res; 1995 Dec; 55(23 Suppl):5817s-5822s. PubMed ID: 7493352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How far have we come with solid (nonhematologic) tumor radioimmunotherapy?
    Breitz HB
    J Nucl Med; 2000 Dec; 41(12):2011-4. PubMed ID: 11138686
    [No Abstract]   [Full Text] [Related]  

  • 11. The immunobiology and immunotherapy of ovarian cancer.
    Bookman MA; Bast RC
    Semin Oncol; 1991 Jun; 18(3):270-91. PubMed ID: 1710393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels.
    Shih LB; Thorpe SR; Griffiths GL; Diril H; Ong GL; Hansen HJ; Goldenberg DM; Mattes MJ
    J Nucl Med; 1994 May; 35(5):899-908. PubMed ID: 8176479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhenium-188--a generator-derived radioisotope for cancer therapy.
    Knapp FF
    Cancer Biother Radiopharm; 1998 Oct; 13(5):337-49. PubMed ID: 10851424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
    J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.
    Visser GW; Gerretsen M; Herscheid JD; Snow GB; van Dongen G
    J Nucl Med; 1993 Nov; 34(11):1953-63. PubMed ID: 8229241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.
    Kotts CE; Su FM; Leddy C; Dodd T; Scates S; Shalaby MR; Wirth CM; Giltinan D; Schroff RW; Fritzberg AR; Shepard HM; Slamon DJ; Hutchins BM
    Cancer Biother Radiopharm; 1996 Apr; 11(2):133-44. PubMed ID: 10851530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies to an epithelial ovarian adenocarcinoma: distinctive reactivity with xenografts of the original tumor and a cultured cell line.
    Baumal R; Law J; Buick RN; Kahn H; Yeger H; Sheldon K; Colgan T; Marks A
    Cancer Res; 1986 Aug; 46(8):3994-4000. PubMed ID: 3731068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer.
    Murray A; Simms MS; Scholfield DP; Vincent RM; Denton G; Bishop MC; Price MR; Perkins AC
    J Nucl Med; 2001 May; 42(5):726-32. PubMed ID: 11337567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.